Current through Register Vol. 50, No. 9, September 20, 2024
A. Each
clinic shall be under the direction of a medical director who shall be a
physician who:
1. possesses a current,
unrestricted license from the board to practice medicine in
Louisiana;
2. during the course of
his practice, has not been denied the privilege of prescribing, dispensing,
administering, supplying, or selling any controlled dangerous substance;
and
3. during the course of his
practice has not had any board action taken against his medical license as a
result of dependency on drugs or alcohol.
B. The medical director shall be a physician
certified in the subspecialty of pain management by a member board of the
American Boards of Medical Specialties, except for the following exemption.
1. A licensed pain management clinic which
has been verified by the department as being in operation on or before June 15,
2005, is required to have a medical director, but is exempt from having a
medical director who is certified in the subspecialty of pain management by a
member board of the American Boards of Medical Specialties.
C. Responsibilities. The medical
director is responsible for the day-to-day clinical operation and shall be
on-site, at a minimum, 50 percent of the time during the operational hours of
the clinic. When the medical director is not on-site during the hours of
operation, then the medical director shall be available by telecommunications
and shall be able to be on-site within 30 minutes.
1. The medical director shall oversee all
medical services provided at the clinic.
2. The medical director shall ensure that all
qualified personnel perform the treatments or procedures for which each is
assigned. The clinic shall retain documentation of staff proficiency and
training.
3. The medical director,
or his designee, is responsible for ensuring a medical referral is made to an
addiction facility, when it has been determined that a patient has been
diverting drugs or participating in the illegal use of drugs.
4. The medical director is responsible for
ensuring a urine drug screen of each patient is obtained as part of the initial
medical evaluation and intermittently, no less than quarterly, during the
course of treatment for chronic pain.
5. The medical director shall ensure that
patients are informed of after-hours contact and treatment
procedures.
6. The medical director
is responsible for applying to access and query the Louisiana Prescription
Monitoring Program (PMP).
a. The PMP is to be
utilized by the medical director and the pain specialist as part of the clinics
quality assurance program to ensure adherence to the treatment agreement signed
by the patient.
i. The treatment agreement
states that the patient has been informed that he shall only obtain and receive
narcotic prescriptions from the clinic where he is being treated for chronic
pain.
(a). The patient shall be subject to
periodic unannounced drug screens and shall not participate in diversion of any
controlled dangerous substance.
b. Compliance to this agreement is to be
determined, evaluated, and documented at each subsequent visit to a clinic when
the patient receives a prescription for a controlled dangerous
substance.
AUTHORITY NOTE:
Promulgated in accordance with R.S.
40.2198.11-13.
